Out-licensing: Generic Version Of Tetrabenazine 25 Mg Tablets

Latest: Watch here for details of new products and services.

About Us: Pharmalicensing - Partnering solutions for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Deal Negotiation; PL Intelligence; Reports; Comparison
PL Intelligence: Overview; Industry news; Deals review; Press releases; Articles
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs
Contact Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd

Out-licensing
View

Generic version of Tetrabenazine 25 mg tablets

Treatment of movement disorders associated with organic central nervous system conditions, e.g. Huntington's chorea, hemiballismus and senile chorea.

Full description

Tetrabenazine 25 mg film coated tablets. This product is indicated for the treatment of movement disorders associated with organic central nervous system conditions, e.g. Huntington's chorea, hemiballismus and senile chorea. Target group are neurologists.

Development status

Preregistration

Patent information

no relevant patents.

Type of business relationship sought

Distribution agreement. worldwide (except of USA).

Licensing contact

Dr. Juerg Fehlmann
Business Development Manager

Contact directly

Company details

Orpha Swiss GmbH

OrPha Swiss is looking of in - and out-licensing opportunities in the field of anaesthesia, intensive care, neurology, pulmonary hypertension and addiction medicine

View profile

Visit website

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Transcytosis of Adeno-Associated Viruses

Rapid and Sensitive Detection of Nucleic Acid Sequence Variations

Low doses of beta-amyloid enhance synaptic plasticity and memory

Butylcholinesterase-Binding Compounds for Monitoring and Inhibiting the Progression of Alzheimer's Disease

Related categories

Industry sector: Pharmaceutical / Generics; Pharmaceutical / Prescription
Therapeutic target: Central Nervous System / Neurological / Huntington's disease; Central Nervous System / Psychiatric

Clients in focus...

Get the Flash Player to see this rotator.

Press releases: Pharmalicensing current industry press releases.

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us